ALLEGAN, Mich., April 12, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version of Mucinex® 600mg tablets) product. This launch consists of product packaged in bottles to a number of customers. The company expects to initiate its full-scale over-the-counter (OTC) launch of product in blister packaging to its retail and wholesale customers in store brand or own label before the end of its current fiscal year.
(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )
Mucinex® 600mg tablets (Guaifenesin Extended-Release Tablets, 600mg), an expectorant indicated to relieve chest congestion and make coughs more productive, has estimated annual sales of approximately $135 million.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another great new product launch for our team and is representative of Perrigo's unwavering commitment to make significant investments necessary to bring complex new products to market. Perrigo continues to focus on making quality healthcare more affordable by expanding our customers' offerings of high quality, value priced products."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Perrigo Company
CONTACT: Arthur J. Shannon, Vice President, Investor Relations and Communication, +1-269-686-1709, ajshannon@perrigo.com, or Bradley Joseph, Senior Manager, Investor Relations and Communication, +1-269-686-3373, bradley.joseph@perrigo.com
Web Site: http://www.perrigo.com